PD-1 Data Promise More Shake-ups In Melanoma Standard of Care
This article was originally published in The Pink Sheet Daily
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.
You may also be interested in...
The PD-1 and PD-L1 inhibitors have delivered stellar data in a number of tumor types and hold mega-blockbuster promise – but with so many in the class, sponsors are looking to stand out. Pull-out table provides side-by-side comparison of leading programs.
During first-quarter earnings calls, sponsors of PD-1/L1 immunotherapies defend their positions in the wake of new data and filings in April, and ahead of the annual ASCO meeting.
After overwhelming but unenthusiastic endorsement from FDA’s advisory committee, the metastatic melanoma immunotherapy could still be hobbled by problematic trials as Amgen seeks approval path and prescriptions in rapidly changing disease space.